Compare RGS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGS | MAIA |
|---|---|---|
| Founded | 1922 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.0M | 77.1M |
| IPO Year | 1994 | 2022 |
| Metric | RGS | MAIA |
|---|---|---|
| Price | $29.50 | $1.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.7K | ★ 495.3K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.24 | ★ 33.33 |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $210,134,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.87 | ★ N/A |
| Revenue Growth | ★ 3.52 | N/A |
| 52 Week Low | $18.23 | $0.87 |
| 52 Week High | $31.50 | $3.19 |
| Indicator | RGS | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 54.47 | 55.69 |
| Support Level | $25.95 | $1.23 |
| Resistance Level | $28.51 | $1.46 |
| Average True Range (ATR) | 1.06 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 64.91 | 89.19 |
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.